MiNK Therapeutics (INKT) Net Income (2020 - 2026)
MiNK Therapeutics (INKT) posted Net Income of -$2.8 million for Q1 2026, down 14.03% sequentially from -$2.4 million in Q4 2025, and down 6.24% YoY from -$3.0 million in Q1 2025.
MiNK Therapeutics (INKT) Net Income (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Net Income for 7 years, with the latest figure at -$2.8 million in Q1 2026.
- Quarterly Net Income fell 6.24% year-over-year to -$2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.0 million (down 47.58% YoY) and the FY2025 annual result came in at -$44.1 million, down 254.97% from the prior year.
- Net Income fell to -$2.8 million in Q1 2026 per INKT's latest filing, from -$2.4 million in the prior quarter.
- Over five years, Net Income peaked at -$2.4 million in Q4 2025 and troughed at -$13.1 million in Q1 2022.
- A 5-year average of -$6.8 million and a median of -$5.5 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2024: Net Income plunged 250.01% in 2022, then surged 61.69% in 2024.
- Over 5 years, Net Income stood at -$7.9 million in 2022, then soared by 30.98% to -$5.5 million in 2023, then surged by 53.97% to -$2.5 million in 2024, then grew by 2.39% to -$2.4 million in 2025, then retreated by 14.03% to -$2.8 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$2.8 million, -$2.4 million, and -$9.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | MiNK Therapeutics | 60.53 Mn | 60.53 Mn | - | -3.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.47 Mn |
| Mar 31, 2026 | -2.79 Mn |
| Dec 31, 2025 | -2.45 Mn |
| Sep 30, 2025 | -9.32 Mn |
| Jun 30, 2025 | -5.41 Mn |
| Mar 31, 2025 | -2.63 Mn |
| Dec 31, 2024 | -2.51 Mn |
| Sep 30, 2024 | -3.29 Mn |
| Jun 30, 2024 | -5.11 Mn |
| Mar 31, 2024 | -3.79 Mn |
| Dec 31, 2023 | -5.45 Mn |
| Sep 30, 2023 | -7.53 Mn |
| Jun 30, 2023 | -10.81 Mn |
| Mar 31, 2023 | -9.90 Mn |
| Dec 31, 2022 | -7.90 Mn |
| Sep 30, 2022 | -12.65 Mn |
| Jun 30, 2022 | -10.96 Mn |
| Mar 31, 2022 | -13.13 Mn |
| Dec 31, 2021 | -7.17 Mn |
| Sep 30, 2021 | -21.45 Mn |